Health Care Stock Winners and Losers: Merck

Merck and Cardiome Pharma pair up to develop atrial fibrillation drug; Lilly continues its rally.
Author:
Publish date:

Health care stocks were ailing Thursday afternoon despite a rally in the broader market.

With the exception of

Eli Lilly

(LLY) - Get Report

, which was up about 1 % to $32.68, and

Procter & Gamble

(PG) - Get Report

, which was inching up 0.4% to $48.67, widely held health care stocks were losing, while the Dow climbed 2.4% and the Nasdaq rose 3%.

Merck

(MRK) - Get Report

and

Cardiome Pharma

(CRME)

announced a partnership to develop a drug for atrial fibrillation, a deal that could result in Merck paying Cardiome more than $600 million. Merck shares were recently falling 1.2% to $26.44

Johnson & Johnson

(JNJ) - Get Report

, which announced that the CYPHER stent outperformed the ENDEAVOR and TAXUS stents in a trial involving ischemia-driven target lesion revascularization and stent thrombosis, was down 0.1% to $51.39.

GlaxoSmithKline

(GSK) - Get Report

was losing 1.6% to $29.58.

Pfizer

(PFE) - Get Report

was down 0.4% to $13.43.

Novo Nordisk

(NVO) - Get Report

was down 0.5% to $43.77.